The Peptide Digest/Industry

2026 Peptide Enforcement Timeline: Every Major Action

·5 min read·The Peptide Digest Staff

2026 has been the most consequential year for federal enforcement against research-peptide suppliers in the modern history of the market. Here is every major action, in order.

March 2026
Peptide SciencesShutdown

DOJ enforcement action — company shut down

March 2026
Amino AsylumRaid

Federal agents conducted enforcement raid on operations

March 2026
Paradigm PeptidesCharges

Federal charges filed

July 2026
FDA Advisory CommitteeRegulatory

Reviewed BPC-157, TB-500, KPV, MOTS-c, Semax, Epitalon, DSIP

September 2026
Apex PeptidesRaid

Raided by USPIS, FBI, and IRS CI — website went offline

The Pattern

The enforcement actions share common characteristics. Targeted companies were operating with marketing strategies — influencer sponsorships, implied dosing guidance, before-and-after testimonials — that regulators view as inconsistent with legitimate research-only positioning. The scale of the 2021–2025 GLP-1 boom drew mainstream consumer attention to peptides, and with it, enforcement attention to the largest and most visible suppliers.

Suppliers that have continued operating through this period share a different profile: conservative compound selection, strict research-only positioning across all channels, and independent third-party testing documentation.

Partner

IQON Health — Research Peptides

Compliant from day one. Third-party tested. Research-use-only. US-based fulfillment.

Browse the catalog →

Frequently Asked Questions

What peptide companies were shut down in 2026?

Peptide Sciences (DOJ, March), Amino Asylum (raided, March), Paradigm Peptides (charges, March), and Apex Peptides (raided, September).

Why are peptide companies being shut down?

Enforcement has focused on suppliers whose marketing implied human use — influencer campaigns, dosing guidance, therapeutic claims — rather than legitimate research-only operations.

Are research peptides still legal to buy?

Yes. Compliant suppliers operating with strict research-only positioning continue to ship. The enforcement targets companies whose marketing crossed the line.

For informational purposes only. Not medical or legal advice.